Ask AI

Advancing Adjunctive Strategies: Optimizing Care for Residual Symptoms in Major Depressive Disorder

Video
This activity is available for 1.00 CME/CE credit(s).

Released: October 27, 2026

Expiration: October 26, 2027

See Activity Collection

Major depressive disorder often remains incompletely treated, with residual symptoms such as anhedonia, cognitive dysfunction, fatigue, and anxiety contributing to relapse and ongoing impairment. This on-demand webcast examines how to assess treatment response, distinguish inadequate treatment from true resistance, and individualize adjunctive strategies based on residual symptoms, prior treatment history, tolerability, and patient priorities.

MDD Adjunctive Strategies

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with MDD do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 45-yr-old man with MDD has been receiving fluoxetine 40mg/day for 10 wk. He reports a 35% improvement on the PHQ-9. He has residual symptoms of low energy and anhedonia. He has demonstrated a partial response to SSRIs in previous episodes. What would be a reasonable next step?

4.

Which one of the following statements is not supported by randomized controlled trial evidence in difficult-to-treat depression?

5.

A 52-yr-old woman with MDD (partial response to sertraline 200 mg/day) has a BMI of 36 kg/m2 and prediabetes and is worried about weight gain and sleepiness. Which augmentation is most consistent with her priorities?